| Marguerite Cullen Weinert, MD | |
|
1000 Wall St, Ann Arbor, MI 48105-1912 | |
| (734) 764-4190 | |
| Not Available |
| Full Name | Marguerite Cullen Weinert |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 7 Years |
| Location | 1000 Wall St, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528596509 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 286961 (Massachusetts) | Secondary |
| 207W00000X | Ophthalmology | 4301509857 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Michigan Health System | Ann arbor, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of Michigan | 3779496856 | 2953 |
News Archive
Today is World Cancer Day 2017, and COCIR is honoured to support its ambition of significantly reducing the illnesses and premature deaths caused by cancer by 20201. COCIR is also proud to highlight the increasingly important role that medical technologies play in achieving these goals, by improving prevention, screening, early diagnosis, treatment, care and palliation of cancers.
The study is reported on July 17, 2013, in an advance online edition of the journal Nature, alongside a British laboratory's structural study of another member of the same class of receptors-known as "class B" G protein-coupled receptors (GPCRs).
Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 (IL2) can extend survival. Now, a combination of IL2 therapy and activation of patients' immune systems using personalized vaccines made from their own tumor cells has been shown to improve survival rates even more than IL2 alone, according to a new article in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
For decades, researchers have tried to understand why breast cancer in younger black women is such a significant public health problem.
Obese patients with early-stage HER2-positive breast cancer may have worse outcomes than patients who are normal weight or overweight, Mayo Clinic researchers found in a study presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth.
› Verified 7 days ago
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568495299 PECOS PAC ID: 3779496856 Enrollment ID: O20031118000092 |
News Archive
Today is World Cancer Day 2017, and COCIR is honoured to support its ambition of significantly reducing the illnesses and premature deaths caused by cancer by 20201. COCIR is also proud to highlight the increasingly important role that medical technologies play in achieving these goals, by improving prevention, screening, early diagnosis, treatment, care and palliation of cancers.
The study is reported on July 17, 2013, in an advance online edition of the journal Nature, alongside a British laboratory's structural study of another member of the same class of receptors-known as "class B" G protein-coupled receptors (GPCRs).
Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 (IL2) can extend survival. Now, a combination of IL2 therapy and activation of patients' immune systems using personalized vaccines made from their own tumor cells has been shown to improve survival rates even more than IL2 alone, according to a new article in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
For decades, researchers have tried to understand why breast cancer in younger black women is such a significant public health problem.
Obese patients with early-stage HER2-positive breast cancer may have worse outcomes than patients who are normal weight or overweight, Mayo Clinic researchers found in a study presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marguerite Cullen Weinert, MD 3621 S State St, Ann Arbor, MI 48108-1633 Ph: (734) 647-5299 | Marguerite Cullen Weinert, MD 1000 Wall St, Ann Arbor, MI 48105-1912 Ph: (734) 764-4190 |
News Archive
Today is World Cancer Day 2017, and COCIR is honoured to support its ambition of significantly reducing the illnesses and premature deaths caused by cancer by 20201. COCIR is also proud to highlight the increasingly important role that medical technologies play in achieving these goals, by improving prevention, screening, early diagnosis, treatment, care and palliation of cancers.
The study is reported on July 17, 2013, in an advance online edition of the journal Nature, alongside a British laboratory's structural study of another member of the same class of receptors-known as "class B" G protein-coupled receptors (GPCRs).
Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 (IL2) can extend survival. Now, a combination of IL2 therapy and activation of patients' immune systems using personalized vaccines made from their own tumor cells has been shown to improve survival rates even more than IL2 alone, according to a new article in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
For decades, researchers have tried to understand why breast cancer in younger black women is such a significant public health problem.
Obese patients with early-stage HER2-positive breast cancer may have worse outcomes than patients who are normal weight or overweight, Mayo Clinic researchers found in a study presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth.
› Verified 7 days ago
Said M Issa, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2900 Golfside Dr, Suite 2, Ann Arbor, MI 48108 Phone: 313-724-2733 Fax: 313-724-2456 | |
Jill Elizabeth Bixler, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall Street, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Paul P Lee, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall Street, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Monte Anthony Delmonte, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall St, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Denise Ann-marie John, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall Street, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Brittany A Simmons, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall St, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Alexander Valentine, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 1000 Wall St, Ann Arbor, MI 48105 Phone: 734-763-8122 |